{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:47:15Z","timestamp":1790264835826,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Among 1306 patients with primary myelofibrosis (PMF), we sought to identify risk factors that predicted leukemic transformation (LT) in the first 5 years of disease and also over the course of the disease. 149 (11%) LT were documented; patients who subsequently developed LT (<jats:italic>n<\/jats:italic>\u2009=\u2009149), compared to those who remained in chronic phase disease (<jats:italic>n<\/jats:italic>\u2009=\u20091,157), were more likely to be males (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) and display higher circulating blasts (<jats:italic>p<\/jats:italic>\u2009=\u20090.03), <jats:italic>ASXL1<\/jats:italic> (<jats:italic>p<\/jats:italic>\u2009=\u20090.01), <jats:italic>SRSF2<\/jats:italic> (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) and <jats:italic>IDH1<\/jats:italic> (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) mutations. Logistic regression analysis identified <jats:italic>IDH1<\/jats:italic>, <jats:italic>ASXL1<\/jats:italic> and <jats:italic>SRSF2<\/jats:italic> mutations, very high-risk karyotype, age\u2009&gt;\u200970 years, male sex, circulating blasts\u2009\u2265\u20093%, presence of moderate or severe anemia and constitutional symptoms, as predictors of LT in the first 5 years of diagnosis. Time-to-event Cox analysis confirmed LT prediction for <jats:italic>IDH1<\/jats:italic> mutation (HR 4.3), circulating blasts\u2009\u2265\u20093% (HR 3.3), <jats:italic>SRSF2<\/jats:italic> mutation (HR 3.0), age\u2009&gt;\u200970 years (HR 2.1), <jats:italic>ASXL1<\/jats:italic> mutation (HR 2.0) and presence of moderate or severe anemia (HR 1.9). HR-based risk point allocation resulted in a three-tiered LT risk model: high-risk (LT incidence 57%; HR 39.3, 95% CI 10.8\u2013114), intermediate-risk (LT incidence 17%; HR 4.1, 95% CI 2.4\u20137.3) and low-risk (LT incidence 8%). The current study provides a highly discriminating LT predictive model for PMF.<\/jats:p>","DOI":"10.1038\/s41408-019-0175-y","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T08:03:57Z","timestamp":1548403437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model"],"prefix":"10.1038","volume":"9","author":[{"given":"Rangit R.","family":"Vallapureddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythri","family":"Mudireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"175_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"175_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi, A. et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124, 2507\u20132513 (2014).","journal-title":"Blood"},{"key":"175_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 32, 1631\u20131642 (2018).","journal-title":"Leukemia"},{"key":"175_CR4","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. MIPSS70+Version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J. Clin. Oncol. 36, 1769\u20131770 (2018).","journal-title":"J. Clin. Oncol."},{"key":"175_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bbmt.2017.09.016","volume":"24","author":"BT Samuelson Bannow","year":"2018","unstructured":"Samuelson Bannow, B. T. et al. Hematopoietic cell transplantation for myelofibrosis: the dynamic international prognostic scoring system plus risk predicts post-transplant outcomes. Biol. Blood Marrow Transplant. 24, 386\u2013392 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"175_CR6","doi-asserted-by":"crossref","unstructured":"Tefferi, A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am. J. Hematol. 93, 1551\u20131590 (2018).","DOI":"10.1002\/ajh.25230"},{"key":"175_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli, P. et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J. Clin. Oncol. 36, 310\u2013318 (2018).","journal-title":"J. Clin. Oncol."},{"key":"175_CR8","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/ajh.24901","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi, A. et al. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. Am. J. Hematol. 92, 1311\u20131317 (2017).","journal-title":"Am. J. Hematol."},{"key":"175_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi, A. et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 1, 105\u2013111 (2016).","journal-title":"Blood Adv."},{"key":"175_CR10","unstructured":"Shaffer L. G., Slovak M. L., Campbell L. J., (editors). ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009) (Karger; Basel, 2009)."},{"key":"175_CR11","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes, F. et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113, 2895\u20132901 (2009).","journal-title":"Blood"},{"key":"175_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia 32, 1189\u20131199 (2018).","journal-title":"Leukemia"},{"key":"175_CR13","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","volume":"32","author":"M Nicolosi","year":"2018","unstructured":"Nicolosi, M. et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia 32, 1254\u20131258 (2018).","journal-title":"Leukemia"},{"key":"175_CR14","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi, A. M. et al. Mutations and prognosis in primary myelofibrosis. Leukemia 27, 1861\u20131869 (2013).","journal-title":"Leukemia"},{"key":"175_CR15","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia 32, 2274\u20132278 (2018).","journal-title":"Leukemia"},{"key":"175_CR16","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui, T. et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J. Clin. Oncol. 29, 3179\u20133184 (2011).","journal-title":"J. Clin. Oncol."},{"key":"175_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000204873","volume":"85","author":"F Cervantes","year":"1991","unstructured":"Cervantes, F. et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 85, 124\u2013127 (1991).","journal-title":"Acta Haematol."},{"key":"175_CR18","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi, A. et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27, 1874\u20131881 (2013).","journal-title":"Leukemia"},{"key":"175_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 32, 1200\u20131210 (2018).","journal-title":"Leukemia"},{"key":"175_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ajh.25053","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. Am. J. Hematol. 93, 649\u2013654 (2018).","journal-title":"Am. J. Hematol."},{"key":"175_CR21","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/leu.2013.207","volume":"27","author":"T Barbui","year":"2013","unstructured":"Barbui, T. et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia 27, 2084 (2013).","journal-title":"Leukemia"},{"key":"175_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1365-2141.2010.08275.x","volume":"150","author":"F Passamonti","year":"2010","unstructured":"Passamonti, F. et al. Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br. J. Haematol. 150, 719\u2013721 (2010).","journal-title":"Br. J. Haematol."},{"key":"175_CR23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez, B. et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88, 1013\u20131018 (1996).","journal-title":"Blood"},{"key":"175_CR24","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","volume":"27","author":"CS Tam","year":"2009","unstructured":"Tam, C. S. et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. J. Clin. Oncol. 27, 5587\u20135593 (2009).","journal-title":"J. Clin. Oncol."},{"key":"175_CR25","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1002\/cncr.23505","volume":"112","author":"J Huang","year":"2008","unstructured":"Huang, J. et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 112, 2726\u20132732 (2008).","journal-title":"Cancer"},{"key":"175_CR26","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi, A. et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J. Clin. Oncol. 29, 1356\u20131363 (2011).","journal-title":"J. Clin. Oncol."},{"key":"175_CR27","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","volume":"117","author":"R Vaidya","year":"2011","unstructured":"Vaidya, R. et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood 117, 5612\u20135615 (2011).","journal-title":"Blood"},{"key":"175_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat, N. et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 29, 392\u2013397 (2011).","journal-title":"J. Clin. Oncol."},{"key":"175_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"Caramazza, D. et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 25, 82\u201388 (2011).","journal-title":"Leukemia"},{"key":"175_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clml.2013.01.001","volume":"13","author":"A Quint\u00e1s-Cardama","year":"2013","unstructured":"Quint\u00e1s-Cardama, A., Kantarjian, H., Pierce, S., Cortes, J. & Verstovsek, S. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid Leukemia. Clin. Lymphoma, Myeloma Leuk. 13, 315\u20138.e2 (2013).","journal-title":"Clin. Lymphoma, Myeloma Leuk."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0175-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0175-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0175-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T11:09:16Z","timestamp":1671188956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0175-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0175-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"19 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"12"}}